Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

18 Jan 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 35072108
DOI: 10.1016/s2665-9913(21)00417-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal diseasePMID 35072108Read ↗

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity Read ↗

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19Semantic proximity Read ↗

Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic diseases patients: phase 4 prospective trialSemantic proximity Read ↗

Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical ConditionsSemantic proximity Read ↗

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boostersSemantic proximity Read ↗

Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseasesSemantic proximity Read ↗

Minimal change disease relapse following SARS-CoV-2 mRNA vaccineSemantic proximity Read ↗

Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseasesSemantic proximity Read ↗

Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationSemantic proximity Read ↗

Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccinationSemantic proximity Read ↗

Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19Semantic proximity Read ↗

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study SaferSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.